Subtype
Differentiated Thyroid Gland Carcinoma
CI-CAN-00005102Explore in graph →
37 active trials3 approved drugs27 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005102Explore in graph →
Clinical trials
185 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (12)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02973997 | Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) | completed | Phase 2 | 57 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT01723202 | Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer | completed | Phase 2 | 53 | Bhavana KondaOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT03037385 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors(ARROW) |
| completed |
| Phase 1 / Phase 2 |
| 590 |
| Hoffmann-La RocheINDUSTRY |
| 13 |
| May 31, 2025 |
| clinicaltrials |
| NCT00381641 | Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT02393690 | Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 60 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT01208051 | Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | completed | Phase 1 / Phase 2 | 127 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2021 | clinicaltrials |
| NCT02138214 | Central Neck Dissection in Patients With Clinical Node Negative Thyroid Cancer | completed | Phase 2 | 117 | University of Wisconsin, MadisonOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00668811 | Sutent Adjunctive Treatment of Differentiated Thyroid Cancer(IIT Sutent) | completed | Phase 2 | 23 | Medstar Health Research InstituteOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00625846 | Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 5 | Feb 26, 2020 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00085293 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT01502410 | Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 3 | Jun 26, 2018 | clinicaltrials |
| NCT01811212 | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2018 | clinicaltrials |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT00729157 | Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00118248 | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT00559949 | Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive Iodine | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 2 | Jan 30, 2017 | clinicaltrials |
| NCT00134043 | Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2014 | clinicaltrials |
| NCT00098813 | Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT00251316 | Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer | completed | Phase 2 | 34 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Feb 4, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Aug 29, 2025source: clinicaltrials